HRP20182020T1 - Liječenje atrofije vagine kod žena u opasnosti od tumorske patologije - Google Patents

Liječenje atrofije vagine kod žena u opasnosti od tumorske patologije

Info

Publication number
HRP20182020T1
HRP20182020T1 HRP20182020TT HRP20182020T HRP20182020T1 HR P20182020 T1 HRP20182020 T1 HR P20182020T1 HR P20182020T T HRP20182020T T HR P20182020TT HR P20182020 T HRP20182020 T HR P20182020T HR P20182020 T1 HRP20182020 T1 HR P20182020T1
Authority
HR
Croatia
Prior art keywords
women
treatment
vaginal atrophy
tumor pathology
pathology risk
Prior art date
Application number
HRP20182020TT
Other languages
English (en)
Inventor
Álvaro ACEBRÓN FERNÁNDEZ
Dolores Blanco Lousame
Jaime Moscoso Del Prado
Concepción NIETO MAGRO
Original Assignee
Itf Research Pharma, S.L.U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41012001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20182020(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Itf Research Pharma, S.L.U filed Critical Itf Research Pharma, S.L.U
Publication of HRP20182020T1 publication Critical patent/HRP20182020T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HRP20182020TT 2008-08-07 2018-11-30 Liječenje atrofije vagine kod žena u opasnosti od tumorske patologije HRP20182020T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200802384A ES2344673B1 (es) 2008-08-07 2008-08-07 Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
PCT/EP2009/060307 WO2010015718A1 (en) 2008-08-07 2009-08-07 Treatment of vaginal atrophy in women with tumor pathology risk
EP09781641.7A EP2328589B1 (en) 2008-08-07 2009-08-07 Treatment of vaginal atrophy in women with tumor pathology risk

Publications (1)

Publication Number Publication Date
HRP20182020T1 true HRP20182020T1 (hr) 2019-01-25

Family

ID=41012001

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20182020TT HRP20182020T1 (hr) 2008-08-07 2018-11-30 Liječenje atrofije vagine kod žena u opasnosti od tumorske patologije

Country Status (22)

Country Link
US (1) US9114143B2 (hr)
EP (1) EP2328589B1 (hr)
JP (1) JP6207118B2 (hr)
KR (1) KR101790652B1 (hr)
CN (1) CN102170886A (hr)
BR (1) BRPI0917265A2 (hr)
CA (1) CA2732877C (hr)
CL (1) CL2011000252A1 (hr)
CO (1) CO6351732A2 (hr)
CY (1) CY1120962T1 (hr)
DK (1) DK2328589T3 (hr)
ES (2) ES2344673B1 (hr)
HR (1) HRP20182020T1 (hr)
HU (1) HUE041377T2 (hr)
LT (1) LT2328589T (hr)
MX (1) MX336154B (hr)
PE (1) PE20110682A1 (hr)
PL (1) PL2328589T3 (hr)
PT (1) PT2328589T (hr)
RU (1) RU2504381C2 (hr)
SI (1) SI2328589T1 (hr)
WO (1) WO2010015718A1 (hr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112334138A (zh) * 2018-05-02 2021-02-05 潘塔希肿瘤学股份有限公司 晚期雌激素受体阳性乳腺癌的治疗
CN110151680A (zh) * 2019-04-10 2019-08-23 重庆医药高等专科学校 雌三醇凝胶产品及制备方法
CN114588252A (zh) * 2022-04-08 2022-06-07 暨南大学附属第一医院（广州华侨医院） 一种用于缓解阴道萎缩和干燥症的组合物及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1866M (fr) 1961-04-07 1963-06-17 Vismara Francesco Spa Nouveaux éthers des hormones oestrogenes.
US4436738A (en) * 1982-03-15 1984-03-13 Mead Johnson & Company Stabilized estradiol cream composition
EP0501523B1 (en) 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
DK0431719T3 (da) 1989-10-31 1995-02-27 Columbia Lab Inc Vaginalt vævsbefugtende præparat
WO1991006289A1 (en) 1989-10-31 1991-05-16 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
IL110024A (en) * 1994-06-15 1998-04-05 Yissum Res Dev Co Controlled release oral drug delivery system containing hydrogel- forming polymer
US5667492A (en) 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
AT408067B (de) 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
US5741525A (en) 1995-10-24 1998-04-21 Marshall University Research Corporation Vaginal pharmaceutical hydrogen peroxide composition
IT1275816B1 (it) 1995-10-27 1997-10-17 Montefarmaco Spa Composizioni farmaceutiche solide per uso vaginale
AU714797B2 (en) 1996-06-14 2000-01-13 Mcneil-Ppc, Inc. Moisture containing compositions that are spreadable onto and adherable to biomembranes, methods of making and use thereof
IT1284874B1 (it) 1996-08-02 1998-05-22 Farmigea Spa Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
DE69739583D1 (de) 1996-11-14 2009-10-29 Lipomedica Ehf Topische zusammensetzungen enthaltend als therapeutisch aktiven wirkstoff ein monoglycerid zur behandlung von schleimhautinfektionen
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6159491A (en) 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
DE69942774D1 (de) 1999-02-26 2010-10-28 Novartis Vaccines & Diagnostic Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
CA2386422A1 (en) 1999-10-22 2001-04-26 Lif-Hlaup Ehf. Bio-Gels Pharmaceuticals Inc. Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion
WO2002011768A1 (en) 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US7709026B2 (en) 2001-10-29 2010-05-04 Columbia Laboratories, Inc. Low concentration of peroxide for treating or preventing vaginal infections
TWI336627B (en) * 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
ES2237298B1 (es) * 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
JP2009504667A (ja) 2005-08-12 2009-02-05 ドラッグテック コーポレイション エストロゲン組成物およびその使用による治療方法
JP2009519926A (ja) 2005-12-16 2009-05-21 ライル コーポレート ディベロップメント インコーポレーテッド エストロゲンの非全身性膣投与による膣組織の再生
EP1971325A2 (en) * 2005-12-27 2008-09-24 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
JP2009523831A (ja) * 2006-01-20 2009-06-25 ペア トゥリー ファーマシューティカルズ インコーポレイテッド 萎縮性膣炎を治療する方法
EP1872775A1 (en) 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
WO2008089405A1 (en) 2007-01-19 2008-07-24 Neurosci, Inc. Composition of multiple hormones delivered vaginally in a single cream
ES2310968B1 (es) * 2007-06-25 2010-02-08 Italfarmaco, S.A. Uso de estriol en bajas dosis.

Also Published As

Publication number Publication date
US20110183950A1 (en) 2011-07-28
HUE041377T2 (hu) 2019-05-28
US9114143B2 (en) 2015-08-25
LT2328589T (lt) 2019-01-10
SI2328589T1 (sl) 2019-02-28
ES2344673A1 (es) 2010-09-02
CA2732877C (en) 2017-04-18
CN102170886A (zh) 2011-08-31
BRPI0917265A2 (pt) 2015-11-10
PE20110682A1 (es) 2011-09-28
WO2010015718A1 (en) 2010-02-11
DK2328589T3 (en) 2018-12-10
CL2011000252A1 (es) 2011-11-18
KR20110045041A (ko) 2011-05-03
ES2344673B1 (es) 2011-05-03
JP2011529951A (ja) 2011-12-15
MX2011001382A (es) 2011-03-29
CA2732877A1 (en) 2010-02-11
EP2328589B1 (en) 2018-09-19
KR101790652B1 (ko) 2017-11-20
EP2328589A1 (en) 2011-06-08
RU2504381C2 (ru) 2014-01-20
CY1120962T1 (el) 2019-12-11
PT2328589T (pt) 2018-12-18
JP6207118B2 (ja) 2017-10-04
RU2011108548A (ru) 2012-09-20
MX336154B (es) 2016-01-11
CO6351732A2 (es) 2011-12-20
PL2328589T3 (pl) 2019-05-31
ES2700614T3 (es) 2019-02-18

Similar Documents

Publication Publication Date Title
PL2426148T3 (pl) Przeciwciało anty-IL-3RA do stosowania w leczeniu nowotworu krwi
ZA201109384B (en) Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
IL213410A0 (en) Methods and compositions for diagnostic use in cancer patients
EP2432462A4 (en) OXYGEN PROCEDURE AND COMPOSITIONS FOR THE TREATMENT OF MAMMALIAN DISEASES
GB0922085D0 (en) Cancer diagnosis and treatment
PT2614832T (pt) Diagnóstico de pré-eclâmpsia
EP2335073A4 (en) IN VIVO DIAGNOSIS AND TREATMENT OF BIOFILM INFECTIONS
HK1170542A1 (zh) 用於癌症患者中診斷學用途的方法和組合物
HRP20182020T1 (hr) Liječenje atrofije vagine kod žena u opasnosti od tumorske patologije
HK1256479A1 (zh) 在治療癌症中grn163l用作端粒酶抑制劑
PL399129A1 (pl) Fulvestrant w dawce 500 mg do leczenia zaawansowanego nowotworu piersi
PT2320900T (pt) Utilização de opioides ou miméticos de opioides para o tratamento de pacientes com cancros resistentes
EP2361317A4 (en) USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER
GB0901837D0 (en) Cancer diagnosis and treatment
GB0917612D0 (en) In vivo imaging agents
HRP20151393T8 (hr) UPORABA BENZIDAMINA U LIJEČENJU BOLESTI KOJE SU p40-OVISNE
HRP20182022T1 (hr) Liječenje atrofije vagine kod žena u opasnosti od kardiovaskularne patologije
EP2336108A4 (en) TRIPYRROL-OCTAARGININE HYBRID COMPOUNDS AND USE THEREOF AS A MEDICAMENT FOR TREATING CANCER AND MICROBIAL DISEASES
GB0821594D0 (en) Improvements in or relating to the treatment of tissue damage
IL220241A0 (en) Use of transferrin in treatment of beta-thalassemias
IL219444A (en) Procine for use in the treatment of blood cell infections
GB0907098D0 (en) Cancer treatment and diagnosis
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer